ArticlePharmacological research2020
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?
Article in Pharmacological research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A comparative study on proinflammatory cytokines interleukin-17A and interleukin-17F expressions in whole blood of patients with COVID-19.Iranian journal of microbiology · 2025Article
- Bridging worlds: a narrative review of IL-17 at the crossroads of inflammation and thrombosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Co-infection withOxford medical case reports · 2024Article
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Article
- The striking mimics between COVID-19 and malaria: A review.Frontiers in immunology · 2022Review
- The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19.Frontiers in pharmacology · 2022Article
- COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges.Cells · 2021Review
- Interleukin-17A (IL-17A): A silent amplifier of COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19.Pathogens (Basel, Switzerland) · 2021Review
- Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients.Journal of personalized medicine · 2021Article
- Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines.Human vaccines & immunotherapeutics · 2021Article
- Genome-scale metabolic modelling of SARS-CoV-2 in cancer cells reveals an increased shift to glycolytic energy production.FEBS letters · 2021Article
- The signal pathways and treatment of cytokine storm in COVID-19.Signal transduction and targeted therapy · 2021Review
- Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19).European cytokine network · 2021Article
- The Novel Coronavirus and Inflammation.Advances in experimental medicine and biology · 2021Review
- May the analysis of 1918 influenza pandemic give hints to imagine the possible magnitude of Corona Virus Disease-2019 (COVID-19)?Journal of translational medicine · 2020Review
- Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.Toxicology and applied pharmacology · 2020Article
- Alcohol consumption and obesity: The hidden scare with COVID-19 severity.Medical hypotheses · 2020Article
- Natural history of COVID-19 and current knowledge on treatment therapeutic options.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.